Xuemeng Liu
Qingdao, 266035, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Discovery of a mitochondria-targeted propranolol conjugate PL37 that induces mitophagy for potent anti-hemangioma activity.
Journal: Bioorganic & medicinal chemistry
Published: May 15, 2026
Design, synthesis, and biological evaluation of a multi-layer-linked idebenone derivative targeting mitochondrial dysfunction and neuroinflammation for ischemic stroke.
Journal: Bioorganic chemistry
Published: May 07, 2026
Co-delivery of panobinostat and siSTAT3 using engineered M1 exosomes to establish a one-two punch therapeutic strategy for glioblastoma recurrence.
Journal: Materials today. Bio
Published: August 02, 2025
A mitochondria-targeted idebenone derivative W1a mitigates cerebral ischemia-reperfusion injury by preserving mitochondrial integrity and suppressing neuroinflammation.
Journal: Bioorganic chemistry
Published: July 08, 2025
Discovery of a potential anti-ischemic stroke agent by suppressing ferroptosis through the ATF3/SLC7A11/GPX4 pathway.
Journal: European journal of medicinal chemistry
Published: April 18, 2025
Super-enhancer-driven SLCO4A1-AS1 is a new biomarker and a promising therapeutic target in glioblastoma.
Journal: Scientific reports
Published: January 17, 2024
The dopamine receptor D1 inhibitor, SKF83566, suppresses GBM stemness and invasion through the DRD1-c-Myc-UHRF1 interactions.
Journal: Journal of experimental & clinical cancer research : CR
Published: September 08, 2023
Comprehensive analysis of PSMD family members and validation of PSMD9 as a potential therapeutic target in human glioblastoma.
Journal: CNS neuroscience & therapeutics
Published: February 20, 2023
Valtrate, an iridoid compound in Valeriana, elicits anti-glioblastoma activity through inhibition of the PDGFRA/MEK/ERK signaling pathway.
Journal: Journal of translational medicine
Published: September 23, 2022
Last Updated: 09/26/2026